Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to the Immunocore 2022 Financial Results and Business Update Call. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to your host, Clayton Robertson, Head of Investor Relations. Thank you.

begin. may You

Clayton Robertson

Welcome call. Daryl. QX XXXX and Thank to results financial you, our

results. Before approvals from indicated views not remind result plans respect of of development like as with call represent including relied would These including Securities we I be begin, with of of in materially those statements Act to statements such and events, as by as update provision the representing differ forward-looking trials, Actual XXXX. subsequent date. should and any prospects within Litigation only performance, Reform filings harbor of expectations events those will statements disclaim clinical the upon you these future as a the may We date our to the forward-looking safe such meaning views and financial specifically commercialization, the factors, statements. include SEC. of under And regulatory various Private this concerning any to contain this our important that our and disclosed obligations webcast and

introduce pleased Immunocore's Dr. Bahija to now I'm Jallal. CEO,

Bahija Jallal

XXXX of Head of you, With Ralph and our and Good Chief afternoon, our everyone. Research Clay. and and me very to Commercial; Head share Head overview of Torbay, our Thank today happy our Brian Di are Officer good Financial Strategy; Berman, David an We're morning performance. Donato, of Development.

the end. be at will take questions We happy to

KIMMTRAK. more there. will that have therapeutics. first, company year, we X the one meaningful stop is can a momentous Immunocore even day not launch with the the delivered makes in XXXX established the it to which of first It was And as leader not every that TCR achieve

we're patients our mission to proud satisfied radically our how never of extremely autoimmune will with with teams and conditions, mission for this in had to We infectious XXXX. benefit. incremental I'm disease stay And and cancer, outcomes improve true advanced

more first the of more KIMMTRAK is trial unresectable than countries, with treatment X the than have and look melanoma. XX for highlights a end in is take since from or at let's we metastatic approved the Phase only and So It XXXX. patients uveal approved KIMMTRAK. XXX now treated

revenues have growth. XX% million $XXX quarter-over-quarter just with We over of

of provide biotech amazing. in make more with about has our more size, team launch performance and achieved even as to a is what available Ralph For our the KIMMTRAK more patients. you our launch to as well will plans countries details

Phase X/X things: at successfully response. we multiple solid responses, pipeline. showing initial presented medical melanoma We X delivered PRAME-AXX passed tumors importantly, research ImmTAC RECIST commercial Our are KIMMTRAK data our tebentafusp, and have the durability to targeting tumor circulating having DNA ESMO, patients Starting in trial. most reduction of teams with with screening and our across with progress teams the advanced with and development [indiscernible] substantial in therapy

Our care. focus as across X/X PRAME-AXX multiple now is of tumor well standards trial increasing the Phase as combination with trial footprint in for types the

addition, new our In have pipeline. in announced we candidates X

PRAME extended. targeting with and PRAME-AXX our therapies expand PRAME-AXX to half-life first The franchise ImmTac

novel immunotherapy first-in-class to PIWIL. Confirming further inhibitors. data and cancer potential our week ImmTac potential is their evaluate aim we the pharmacodynamic CROI. at GI just ImmTac checkpoint patients presented presented our we HIV therapy, colorectal of with are The a a last functional for this targeting platform, which our last first with one, our insensitive HBV third other safety the far year, has exciting and an tumors, is candidate so PIWIL one potential is the cure. in With activity as HIV and to

XXXX. see, you a we busy very productive As had can and

into runway goals our projected ambitious placed well us taking to financial are XXXX. We with these deliver

Ralph. now to over will I hand it

Ralph Torbay

NCCN year. launch outcomes over on update patients to with radically it Bahija. recommending and delivered innovative Thank the drug provide a through very melanoma. to into of metastatic for delighted as with award the what be the improving you an of standard today therapy successful strongly promise we best script. France uveal This care and with XX KIMMTRAK, against for patients has [indiscernible] and the launch of in with mUM have KIMMTRAK I'm Approvals recognized living from guidelines, and was in countries here you, the been inclusion prestigious award from new a ASCO

countries U.S., transitioning net flawlessly HLA-AXX:XX sales medicine that supply all metastatic within KIMMTRAK we've primarily EAP countries. executed just of positive patients patients launching all recognized to In reimbursement and most Germany $XXX have across major after in. we in the KIMMTRAK, weeks the launched importantly, teams France, for achieving days approval, KIMMTRAK Our XXXX, as in tubulomynoloma commercial prescribed and in million establishing X

single-digit net France. including represents by specialty XX% QX onetime $XX approximately sales driven demand Our the U.S., a growth. quarter-over-quarter demand of Germany in in in growth and was a million and strong year-end stocking our This distributors at increase

accounts the progress expect the our patient and at moving plan what the the believe look KIMMTRAK new team number now forward. our to accounts, We XXXX. to potential, and we capture in new these community. by increasing of execution in XX% outstanding XXX The Let's delivered U.S. of especially to U.S. in continue approximately

future is first with closed in and being important treated KIMMTRAK closer to of Our of were line, of X community. end our patients At we the enabling XX% home focus on XXXX, in share the the the of out for patients X therapy. being first-line patients, year treated

efficacy the our reported see real-world tolerability Phase in KIMMTRAK to X of out playing pleased clinical trial setting. I'm the and in

which our a duration average around to duration commercial months, X expectations. in broadly indicate therapy line KIMMTRAK to early remains persistence is mean it our While with is of the of models that tracking of therapy, confirm

job of coverage all saw From covered. an teams year, access perspective, And done last XX% policy formal the we XX% a patients of tremendous our have for over potential in in U.S. prescription securing

who single work needs to KIMMTRAK every to goal continue our of program. patient Connect for We our supporting hard KIMMTRAK towards access

launch [indiscernible] had which key with KIMMTRAK ongoing support benefit their these KIMMTRAK have move physicians the markets. where Germany dermato-oncologist France. working with in by has in XXX Let's GBA Germany products value office-based with last of with price are footprint important patients particularly in our accounts a as This first fantastic becomes into XX clinical With increasing capturing only The potential patients the European The KIMMTRAK years and over with by well. treatment added patients all our will line France, treating Germany is in are and strong efforts treated team rating, dedicating received nearly on in recognized to mUM we Europe, to in across to of a KIMMTRAK considerable as expand we've a X to X oncology been rating. negotiations.

the German half as first retroactively November We expect negotiated XXXX. a in net will and reach of started accruing have discount apply year. by price negotiated price sales potential This to our for we the of this

KIMMTRAK France, in we early In clinical have expected agreement received for access more the XXX XXXX. rating patients X with this improved and negotiations will rating over mUM no enable us and have One of launched we strong X second of began XXX an pricing first we has and for begin our to is in benefit of not to an XXXX, successfully then patients was relevant year of and SMR the With innovation than comparators, patients, XXXX patients. half with ASMR restrictions importance. half ago, historic outcomes that program a delivering year Today, Immunocore. countries, benefited the amazing globally. certainly for radically in

not in our midyear to up and available, EAP. patients in to yet expect making launch one to country available Looking major to countries KIMMTRAK KIMMTRAK ahead, countries on additional XXX around European KIMMTRAK to of Across reimbursement nearly we continue is over by ambition X,XXX by focused the remain patients XXXX. offer through we year-end. We where X

I for want With excellent And thank our that, take invite XXXX. support. through you you Thank for financial team Brian results. I to an your to now the

Brian Di Donato

you, XXXX later unless Thank to into SEC XX-F and our Form XXXX. provide discussed and stated. refer results. financial will on financial for convenience the rates XXXX quarter using morning U.S. versus fourth this release and on we some year-end filing we third otherwise Please press in the dollar Today, today insights highlights Comparisons quarter our Ralph. the issued full focus

nearly financial QX QX, to expand of On teams net the Germany XXX to Total I'm Slide the France, some XX% with and saw continue a the KIMMTRAK XXXB and In seamless summary as countries net expansion of early United both in our produced quarter in XX, that excited when was onetime deliver due over U.S. currently our we to part which dollars, U.S. access mentioned, fourth report adjustment stocking site net, in execute continuing increased In impressive results. gross to to sales patients. our to and increase Medicaid and $XX.X and you treating Ralph patients year-end while XX% a vial States, and in the we year-end program U.S., see million an increase new in of Europe. converted the QX. to reimbursement assumptions. sales, global revenue, to

final sales, revenues and decreased continue to In Europe, November Germany, pricing even net new million QX. to due X increase on until an for expected reimbursement with in will started vial which $XX.X agreement in accruals

KIMMTRAK to portfolio. into capitalized cash R&D translated increased $XX plans, British With currency equivalents throughout projected $XXX $XX.X with and million XXXX side, accelerate $XX.X the candidates. our as marginally back provides U.S. portfolio dollar are clinical XXXX QX, million a new revenue, to at the SG&A of quarter million ImmTACs company runway we million with due partly has and On on for current our The this development cash over the expenses great to increase increased it's loss when a pounds. to expand expense in including and in expected reserves year-end. development to

European U.S., we and year-end. KIMMTRAK new accounts, XXXX. as which academic as XXXX. On Europe, move formal country Ralph community to some KIMMTRAK it launch new countries which these lower of reimbursement X Germany in France centers, dynamic key will is into in agreement be into by oncology one for of of key opportunity for lower a ahead. be may well density growth we the looking commercial we drivers midyear, lead expected you by tend rates growth additional than U.S. one additional summarizes to as insights major In XX, Slide head the as and has shared some expected with the In

real-world it's know early still to Globally, too ration of treatment. too

X However, trials. observed currently, we approaching in the clinical the months are

drug for we receive consistently and USP XX an exemption as required Refund TAP rebate requires Another of the discarded a the of request QX CMS for to rebate our portion drug sales KIMMTRAK. We follow regarding XXXX, consideration of patients to is micrograms from manufacturers CMS in guidance FDA safely ensure Act. a and U.S. events. may fill Starting in CMS plan XXXX seek CMS to KIMMTRAK.

Given moving and team's of bringing the it The KIMMTRAK early sales guidance I accurately patients to and extremely melanoma. globally, are health to metastatic still patients support execution in we and XXXX, the revenue too the provide and number for forward pleased targets continuing with look to to uveal year. is commercial team with

over who will our David, call will David? I to updates. turn review now the portfolio

David Berman

much, Thank Brian. you very

We is melanoma also expressed have which uveal first as KIMMTRAK melanoma. GpXXX are for target cutaneous brought proud is in the medicine other including metastatic KIMMTRAK, melanoma. very the types, to approved of

screening in estimate a of All now of replicated with to treated previously endpoint. in to early trials tebn this a this initiate survival observed The confidence indication in opportunity in signals gives is the mUM we melanoma and us program cutaneous patients, melanoma. the melanoma, size Xx in are efficacy cutaneous the uveal also Xx study we is and registrational for

showed PRs expansions by expand is combinations. that and enrolled trial melanoma GpXXX a X And as last data, durable FXXXC uveal lead cutaneous of to a around solid we specific targets to strength other go And this melanoma is X as in our we PRAME The At with ESMO peptide the target. opportunity melanoma, in presented program, we have the footprint now well monotherapy invested PRAME, have the building focus year, tumors. ovarian target. carcinoma. based Phase induced And a HLA-AXX. and FXXXC on the globally to franchise

to expect 'XX. first of efficacy We by half have data the

presented that that is multiple targets the half-life extended for lead XX%. Japan a for we X and as peptide bringing peptide We announced that very program for with PXXXC addressable example, the in and know has tebentafusp positive AXX. platform the active PRAME will same with we solid patients HLA-AXX population an January, XX% months. expand IND by targets in dramatic are the benefit. potential current In by tumors next will of HLA-AXX a durable new half-life. our survival alone, PRAME impacts be In PRs this XX standard to TXXXC a

version, convenience. our are which given an could investing patient in HLA Nevertheless, PRAME, enhance also we for enthusiasm

unique tumors. engine prognostic I'm target targets pipeline has features cancer of role boundaries reminiscent PIWILX. a one colorectal patients. we which negative PRAME, broad present will it using a push PIWILX in discovery tumor about in marker, of And of progression. important several novel solid to expression suggesting TCR Our that here, PIWILX to it's has have of where a unlock an called [indiscernible] TCRs the delighted has is homogenous

And CRC addressable checkpoints, of for IND insensitive year to has and this per reminiscence population melanoma. year. patients an We historically is the is uveal been XX,XXX fourth of planned believe quarter

reservoirs therapy functional And viral of TCR and are cancer, reservoirs. it or residual goal also Our to current was cells therefore, apply remove cannot logical Both but scan for HIV. eliminate by T the technology infected these eliminate specifics virally have where for virus. attempt cells. to our therapy they HBV to The scan

the as with living no XXXV, CDX last induced We The HIV the of safety a syndrome, and ascending the works dose dose to antiretroviral recruiting is HIV trial have well cells the blood. T tolerated was very in strong a cytokine stable of our primary and enthusiasm multiple portion dose a people was cell. holes identified who year but with by for clinical on opened are had micrograms infected potent identify IL-X in punch XX HIV at We portion. HIV cell T dose release killing that ImmTAC in to CDX infected single enrollment T ascending and therapy. the objective cytotoxic

the our We redirection oncology for in provides to and a and found to IL-X to of reason downstream and consistency from have programs disease is engagement biomarker is that oncology move T sensitive this us infectious cell MAD. striking

stopping to X will on We endpoint and safety where receive early believe We ImmTAC are HIV of MAD participants at antiretroviral decrease HIV affect this but functional X the dose, rebound. opened determine if have for of months also portion to the Phase including months can the of keen now see and antiretroviral a XXXV to slow magnitude antiviral the living provide primary trial after care. we XXXV top of very or a and activity, viral with The X POC treatment therapy. we kinetics look should

Bahija. hand now I'll to back

Bahija Jallal

Ralph. Thank you, David, Brian, and thank you,

and heard, for transformative have you As the XXXX company. was an amazing year

that in We patients you have to heard, treatment infectious oncology launched offer chapter ImmTAC definitely the pipeline and platform reflects we cancer written now as diseases. also across This pioneered next as types, KIMMTRAK. our the large many and can potential just

and breadth candidates. to of need portfolio the our prioritize pipeline, continually depth Given we our

ImmTAC have You'll removed note we our that targeting candidate MAGE-AX(AOX).

of co-funding opted our our out on agreement have Genentech, PRAME. with We given focus

we is leader commercial eligible are the we receive on milestones therapeutics. based collaboration, building development the pipeline advances if TCR of the which therapy. In MAGE-AX(AXX) This to Genentech growing as in will robust a Immunocore continue

report into company. biotech that date. stage we commitment commercial a and delivering XXXX now QX runway I'm to such allow is a very XXXX for continue and our us as done against Immunocore have cash to officially, revenues So will proud to

is in even the context year what biotech performance another significant of the has Our been challenging sector. for more

as wrap ahead. we for the our So I'm up remarks, excited year

on was So transformative will if those be a year, a expanding year successes. XXXX XXXX

Our priorities clear. are

melanoma cutaneous and on growing the focused are trial. launching KIMMTRAK We enrolling and

patients For in the combination in of well our PRIME and increasing multiple in program, as care. with we as site are footprint investing types standards enrolling tumor

therapy XX later oncology, in an are file the months. targeting our the IND first-in-class this plan franchise we for Also year. PRAME PIWILX with INDs towards We expanding eye multiple in an also next to

step of ascending and we trial cash way. multiple portion way every the dose we disease, way, HIV to the identify part activity infectious a single have Along dose we the ascending started functional of also antiviral have will cost cure. been and on a focus and to to discipline safety continue that lead And the finished could the

So urgency sense for and improve do same of XXXX, so as to we outcomes radically patients. we determination with drive, enter

and as thank to investors -- thank for and our But I our I and With patients every most at importantly, to your thank want want Immunocore. that you our families. I shareholders to want employee single their support.

the And the for questions. Thank to call be team we'll your with questions, open I'll happy take now, and you.

Operator

Jefferies. question Michael the Our comes with [Operator Instructions] first Yee from of line

Michael Yee

great Two Congrats on a year. questions.

you so the to run On what the the a help KIMMTRAK And there Could net like get U.S.? XXXX? some growth sales us underlying inventory. was in XXXX describe into number U.S., for looks you then going some that impacts like the the understand very also you help there. gross of what mentioned number strong were good throughout could positive was us onetime in just there rate And demand a quarter, fourth rate there think that and

PRAME, a on what think and cohorts. bar maybe for you're data? about to for the Can lung for enrolling question expectation a Phase Phase know cancer and the then David. bit X lung cancer, And I expansion size us about or X you've good how little you given previously talk right is lung what cancer or help to us seen you the the

Bahija Jallal

Great you, first David. questions. then the and you’ll Brian, Michael. take one Thank

Brian Di Donato

Yes.

mostly X those for So that and a they're more increase we in that million. a about gross we QX. little $X use. bit in specifics so about saw probably stocking $X XXX Michael, in reduction some We're the million to increases net, conservative, assumptions Together, around

real million around end it in was So the $XX demand. probably U.S. $XX instead of million being

in in community the benchmarking. QX have as most number we growth or slower we're centers, growth, that's the expect as moving penetrated you now we a U.S. should pretty into in to good as have XXXX of mentioned, saturated be So probably we And and move for academic

discount of QX. for is versus we'll have other The another QX dynamic German month

as perspective. little more it bit that will from reduce a So well a benchmark

David Berman

Yes, would guess Michael, X in answer I ways. it I

tumor. The is a is very first that lung complex

So we to study need different populations.

mutation IO we're course, of is For example, studying And patients insensitive. EGFR on checkpoints. now the ALK historically also failed who've

get there's endpoint. lung of of I response any ctDNA into confidence looking is And active activity, expectations for opportunity RECIST we’re for ways. what we to think line. that we’re of PFS. looking would FXXXC But in the i.e., Is So is complexity terms look it account. we’re or need then evidence looking for, I in in there Is rate there take confidence to X One reductions? at that

think at. activity levels so are looking of that And those the we're X I

Operator

come with questions line next of Our the from Jessica Fye JPMorgan.

Unidentified Analyst

This on [ph] is did Jess. mentioned therapy the towards weighted or other? more XX% about you versus is line patients U.S. on Nick region the first-line Today, line for that that across hold you're in How that XX%, Or first does or Europe? the study. true second heavily one --

Bahija Jallal

you take one. Ralph, can Great. that

Ralph Torbay

for you thank question. Nick, the

So look, patients U.S., in the in seeing the XX% we are line. first KIMMTRAK of

in second around duration are that’s we So seeing first on the line line. the remainder of That’s see increasing where therapy. in we Europe, our plus. and where where XX%, In because is Germany focus of and them OS see we’re that’s France, focused specifically we’re

increasing on high focused that as We’re get as we can it.

Operator

line next Cowen. questions come from Our Buren Tyler Van the with of

Unidentified Analyst

Tara on [ph] is This for Tyler.

expansion half that year you updates are expected conferences? And that any a there other at PRAME data forward the when could is to? of those of in there come say the that maybe XXXX, we ESMO later can by data chance look it So XXXX, or one first this are dose

Bahija Jallal

invest was the strategy early into our expanding -- to footprint the footprint. the really clinical for It’s Yes.

team comprehensive that’s and focus any we on the the think exactly that’s development, monotherapy the And with takes I multiple it’s that longest. combination. what for pretty that the program a want plus drug to arms in what

focus, first and we’ll why So we that’s globally data and the bring XXXX. said that’s going the half by of we are the really

Operator

next with from the line Our of comes H.C. Trucchio Patrick Wainwright. question

Patrick Trucchio

on actually capital have allocation I the a follow-up focus. question

achieve these can capital with revenues I’m for R&D these new focus as How might next multiple KIMMTRAK on the pipeline with the through and you you ramping, do balancing in when pivot year focus balance priorities? profitability. the profitability? wondering emerge. Specifically it particularly while allocation And programs discuss if eventual and beyond, development to potential to continue relates and the company the programs development

Bahija Jallal

Thank is for Brian. and Yes. our you Really, Thank the you. question. expanding then focus the pipeline. I'll start

seen, what dollars As pipeline the be and have you the that's will we will expanding, go -- exactly there. is

important. I think it's very

some that comment We on But as have you well? assets. to great do Brian, want

Brian Di Donato

Yes. Great Patrick. question,

research If PRAME ImmTAC consistent PRAME-AXX, last the pretty our expenses we’ve like we’ve extension X you at over PIWIL, new expenses, with well in and years, to expenses. able research been our those been these half-life look research deliver molecules

and the it’ll advanced don’t scale would dramatically. to be we will need as many you the we in expect really PRAME. PRAME. Well, to pivotal change trials and part So what that cost by driven will would as change be And expect, run we for move development how large large

that’s So we’re focused. where

those in now. budget We have the

milestones You’ll on and able of move co-funding expansion. forward. And MAGE-AX receive and notice with co-development they we did opt of MAGE PRAME and in the be appreciate with we’ll the from still them focus that as out collaboration be that to the if we royalties still we Genentech, however, collaboration

Operator

comes Our of Kim Oppenheimer. the next from question Justin with line

Justin Kim

regards compare might And experience, median HLA-AXX be how trial managing the [indiscernible] are does have tools any to patients additive the any to With intake the there of perhaps how to patient? observationally experience against are the physicians negative benchmarking potential situations on clinical progression? team the through duration, to

Bahija Jallal

Justin. Great,

think you I and the clinical where with we ahead. are DOT can Ralph about compared go talk trials,

Ralph Torbay

medicine, are patients really see and patients trial seen the the physicians is we and when in the we the clinical that that trial that really true in are way intended. world new safety in the medicine seeing And benefit. that are it's is physicians and we've able replicated that look, benefit and seeing the use the to the real Justin, means experience the efficacy launched clinical a because great being the

that’s trial. So tracking you X mean, the from And what medium in we from saw we’re we’re at a perspective, exactly recall, a clinical if to X months. And months.

that keep keep As we treatment aspect. educating progression, aspect that on subset educating on beyond or we that relates progression,

we’re seeing tracking we treatment of seeing duration patterns similar today, -- in course, very what to months. mean to is which why X also Of accounts, to this academic we’re see treatment at

Operator

Our next the from of comes Justin question with BTIG. Zelin line

Justin Zelin

Maybe just kind in duration far could thus of of in think prior therapy, a just on possible that extension duration follow-up tick expect the you that mirroring real question of therapy. the trials the world? with Or Do seen see clinical the do that this you follow-up what on results you more here? it’s

Bahija Jallal

ahead. Go

Ralph Torbay

So Justin, expect. that’s what we

so to in expect we’ve staying growing clinical tale. somewhat then trial. And a the and what and by the to seen you driven trial the not We if see median clinical far mostly look see at the the clinical our you mean same trial, that’s significantly,

that treating physicians do in use if the the where think we’re we I going. longer significantly, we So way and they’re growing, be do benchmark the can not is the treating, market, you to the expect the clinical mean trial expect keep see to this

Operator

comes Barclays. Our with Peter line the of question Lawson next from

Peter Lawson

KIMMTRAK? the that follow-up help a think just where treatment extension, well? duration do could as for could convenience? is And settle of with patient durability more for you Or think that around of guess half-life I eventually you here, that

Bahija Jallal

Yes. Great.

duration I think half-life expected David extension. and on Ralph you the maybe take -- the

Ralph Torbay

in is duration will of overall the upcoming can our I update So, give include conference. at going survival, therapy that of answer be providing we're an which to I best you an PFS think X-year

you So look a that. at take I to invite

David? to go. treatment So expect you mean where of can duration see we the

David Berman

what’s with ratio saw benefit we of half-life hazard hours, KIMMTRAK with a with of survival X X.XX. Yes. know a Peter, plasma you remarkable

course, So we our know platform of that very highly current active. is,

about improvement it’s on open think a just in durability. be data whether I half-life an driven have that. extension We’ll efficacy any will question have or to

Operator

Jeff the comes Stanley. Our with next of from question Hung line Morgan

Jeff Hung

ctDNA can is And you then melanoma, treating advanced And do PRAME, think using to for you do how how X? to get in in why that Phase And there? you endpoint predictive be multiple X? think done you’re needs HLAs? about Phase survival what For about talk for

Bahija Jallal

Great David? Right. question.

David Berman

ctDNA can survival. So dual that reason we’re decisions gives make read II it. The that drop for ctDNA so both earliest is are of melanoma, i.e., repower Phase for the us the the arms, the the doing endpoints one the overall because the for X, Phase and we fastest advanced

We at because We to realize also directional have that will we cutaneous mature it though, to also estimate an whether point, going give power but designed realized a survival We It’s us enough yet a validated have we trending. survival that. completely is to melanoma, won’t look. look. survival designed ctDNA get it in be about not is

So really ctDNA. that’s for reason the the

With I think PRAME. the you’re second that regard different to alleles Is about for question, Correct? asking

Bahija Jallal

Yes.

David Berman

AX, opportunity. allele that’s after we allele XX% And announced the to this estimate and We most and it population patient will it are AXX pursuing develop we why HLA-AX for take apply So PRAME AXX, HLA attractive the HLA-AXX. make faster. that from this increase learnings we’ll the to the opportunity from a

Operator

Sachs. Looks line questioner. [Technical through from lost to next like Nick. next the the of Nick Goldman I'm Our we with Difficulty] Gallo question bring going comes

come with the questions Ladenburg next Thalmann. Demir line from Our of Ahu

Ahu Demir

more the progression Could on color good a on and question KIMMTRAK. first discontinuation My quarter rates treatment world? beyond real Congrats you a provide and is in year. maybe on

Bahija Jallal

to... want you do Ralph, you. Thank Great.

Ralph Torbay

Great question.

are in we with line discontinuations treatment to be what clinical the the experience. So we expected in seeing trial

from progression, reasons beyond perspective have look the medical treating great our see you we beyond obviously, do for discontinuation always conversations into and really ask We're that’s progression. physicians. the surprises, a that not to fact, with regard what well. whether treatment we In they're affairs closely seeing we With tracking real world. when at which very go any is we of part are they is comfortable to And then physicians,

comfort. so level that far, are seeing And of we

the we we're focused education on. what community, more to as go be and into needs that’s course, Of had,

Bahija Jallal

Yes.

academic good are the that really there ones a is actually beyond there it's -- centers, in think investigators I point benefit because who the progression. saw the

into community, will there and MSLs go So to is the science the but think work we done I that's education and the where the when more in. be come

Operator

There call no back closing now are Jallal over to I further questions for this Bahija hand would time. any to remarks. like at the

Bahija Jallal

Yes.

and support, much questions, so you going for call. you. thank your your we’re close and the for So, you to Thank now thank

Operator

This you. We today's teleconference. your conclude participation. Thank appreciate does

You this the may rest day. lines at Enjoy your of time. disconnect your

Immunocore (IMCR) 1 Mar 232022 Q4 Earnings call transcript